Literature DB >> 33993135

Psychedelic-Assisted Therapy: Emerging Treatments in Mental Health Disorders

Andrew Penn1, Caroline G Dorsen, Stephanie Hope, William E Rosa.   

Abstract

Psychedelics are a class of psychoactive substances that were studied extensively between 1943 and 1970 as potential therapies for treating a host of mental health disorders, including addiction. Despite promising early results, U.S. psychedelic research was halted in the early 1970s with the enactment of the Controlled Substances Act. As the field of psychedelic-assisted therapy develops, nurses can decide the role they will play in the continuing clinical and scholarly research of these substances, which may soon be used in controlled settings to treat some of the most widespread mental health disorders. To prepare for this task, this article proposes that nurses * become familiar with the history, relevant language, and scientific findings related to the field of psychedelic research. * learn about existing psychedelic-assisted therapy and research resources. * examine their thoughts, judgments, and opinions about therapeutic psychedelic use. * consider the potential role of nursing in psychedelic-assisted therapies going forward.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33993135      PMCID: PMC8574982          DOI: 10.1097/01.NAJ.0000753464.35523.29

Source DB:  PubMed          Journal:  Am J Nurs        ISSN: 0002-936X            Impact factor:   2.577


  28 in total

1.  SUPPORTING THE PATIENT ON LSD DAY.

Authors:  K PARLEY
Journal:  Am J Nurs       Date:  1964-02       Impact factor: 2.220

2.  The State of US Health, 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States.

Authors:  Ali H Mokdad; Katherine Ballestros; Michelle Echko; Scott Glenn; Helen E Olsen; Erin Mullany; Alex Lee; Abdur Rahman Khan; Alireza Ahmadi; Alize J Ferrari; Amir Kasaeian; Andrea Werdecker; Austin Carter; Ben Zipkin; Benn Sartorius; Berrin Serdar; Bryan L Sykes; Chris Troeger; Christina Fitzmaurice; Colin D Rehm; Damian Santomauro; Daniel Kim; Danny Colombara; David C Schwebel; Derrick Tsoi; Dhaval Kolte; Elaine Nsoesie; Emma Nichols; Eyal Oren; Fiona J Charlson; George C Patton; Gregory A Roth; H Dean Hosgood; Harvey A Whiteford; Hmwe Kyu; Holly E Erskine; Hsiang Huang; Ira Martopullo; Jasvinder A Singh; Jean B Nachega; Juan R Sanabria; Kaja Abbas; Kanyin Ong; Karen Tabb; Kristopher J Krohn; Leslie Cornaby; Louisa Degenhardt; Mark Moses; Maryam Farvid; Max Griswold; Michael Criqui; Michelle Bell; Minh Nguyen; Mitch Wallin; Mojde Mirarefin; Mostafa Qorbani; Mustafa Younis; Nancy Fullman; Patrick Liu; Paul Briant; Philimon Gona; Rasmus Havmoller; Ricky Leung; Ruth Kimokoti; Shahrzad Bazargan-Hejazi; Simon I Hay; Simon Yadgir; Stan Biryukov; Stein Emil Vollset; Tahiya Alam; Tahvi Frank; Talha Farid; Ted Miller; Theo Vos; Till Bärnighausen; Tsegaye Telwelde Gebrehiwot; Yuichiro Yano; Ziyad Al-Aly; Alem Mehari; Alexis Handal; Amit Kandel; Ben Anderson; Brian Biroscak; Dariush Mozaffarian; E Ray Dorsey; Eric L Ding; Eun-Kee Park; Gregory Wagner; Guoqing Hu; Honglei Chen; Jacob E Sunshine; Jagdish Khubchandani; Janet Leasher; Janni Leung; Joshua Salomon; Jurgen Unutzer; Leah Cahill; Leslie Cooper; Masako Horino; Michael Brauer; Nicholas Breitborde; Peter Hotez; Roman Topor-Madry; Samir Soneji; Saverio Stranges; Spencer James; Stephen Amrock; Sudha Jayaraman; Tejas Patel; Tomi Akinyemiju; Vegard Skirbekk; Yohannes Kinfu; Zulfiqar Bhutta; Jost B Jonas; Christopher J L Murray
Journal:  JAMA       Date:  2018-04-10       Impact factor: 56.272

3.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors:  R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

4.  MDMA enhances emotional empathy and prosocial behavior.

Authors:  Cédric M Hysek; Yasmin Schmid; Linda D Simmler; Gregor Domes; Markus Heinrichs; Christoph Eisenegger; Katrin H Preller; Boris B Quednow; Matthias E Liechti
Journal:  Soc Cogn Affect Neurosci       Date:  2013-10-04       Impact factor: 3.436

Review 5.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

6.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

Review 7.  The harmful health effects of recreational ecstasy: a systematic review of observational evidence.

Authors:  G Rogers; J Elston; R Garside; C Roome; R Taylor; P Younger; A Zawada; M Somerville
Journal:  Health Technol Assess       Date:  2009-01       Impact factor: 4.014

8.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

9.  MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Authors:  Michael C Mithoefer; Allison A Feduccia; Lisa Jerome; Anne Mithoefer; Mark Wagner; Zach Walsh; Scott Hamilton; Berra Yazar-Klosinski; Amy Emerson; Rick Doblin
Journal:  Psychopharmacology (Berl)       Date:  2019-05-07       Impact factor: 4.530

10.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

View more
  1 in total

Review 1.  The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.

Authors:  Cindy A Stein; Andrew Penn; Stephanie Van Hope; Caroline G Dorsen; Mariavittoria Mangini
Journal:  J Midwifery Womens Health       Date:  2022-05-06       Impact factor: 2.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.